Patents Examined by Ganapathy Krishnan
  • Patent number: 10736888
    Abstract: The invention provides a combination comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof, mupirocin or a pharmaceutically acceptable derivative thereof and neomycin or a pharmaceutically acceptable derivative thereof. This triple combination is particularly useful for the treatment and/or prevention of microbial infections.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: August 11, 2020
    Inventors: Anthony Coates, Yanmin Hu
  • Patent number: 10729709
    Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: August 4, 2020
    Assignee: Piedmont Animal Health Inc.
    Inventors: Neil E. Paulsen, Gail L. Dempsey, Michael S. Daniel, Tiffany G. Tomlinson, Douglas Hepler, Raymond Petzold
  • Patent number: 10723751
    Abstract: Provided are cyanogenic compositions for treating diseases, such as infectious diseases.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: July 28, 2020
    Inventor: Laszlo Sichtnik
  • Patent number: 10722575
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: July 28, 2020
    Assignee: GENFIT
    Inventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
  • Patent number: 10722574
    Abstract: The present invention relates to beta-glycolipid derivatives, their preparation and use as adjuvants in vaccines, as being suitable for being co-administered with antigens for vaccine prophylaxis and therapy. In certain embodiments, the beta-glycolipid derivatives of the invention also in their salified or complex form, are suitable for being co-administered with antigens for both therapeutic and prophylactic purposes or for vaccine prophylaxis and therapy.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: July 28, 2020
    Inventors: Angelo Fontana, Emiliano Manzo, Adele Cutignano, Raffaele De Palma
  • Patent number: 10716959
    Abstract: There is provided polymer-flavonoid conjugates. Flavonoid-grafted and flavonoid-terminated polymer conjugates are disclosed according to the invention. The linkage of flavonoids to the polymers has been achieved via thiol linkages. The inventive processes allow for making of the conjugates in high yield avoiding complex purification steps. The conjugates can be easily autoxidized to hydrogels with uses in many biomedical applications where a higher stability of the flavonoid is necessary. The hydrogels can be potentially used as viscosupplement, anti-adhesion film or dermal filler.
    Type: Grant
    Filed: September 1, 2014
    Date of Patent: July 21, 2020
    Inventors: Motoichi Kurisawa, Ki Hyun Bae
  • Patent number: 10716803
    Abstract: Described herein are methods of treating a subject that has been or will be exposed to radiation, trauma or shock, the method comprising identifying a subject that has been or will be exposed to radiation, and treating the subject with a compound that treats, reduces the severity or delays the onset of sepsis or reduces the likelihood of mortality in a subject upon administration of a therapeutically effective amount the compound to the subject.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: July 21, 2020
    Assignee: SYNEDGEN, INC.
    Inventors: Shenda M. Baker, William P. Wiesmann
  • Patent number: 10709817
    Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: July 14, 2020
    Assignee: Tricol Biomedical, Inc.
    Inventors: Barbara McGrath, Simon McCarthy, Sam Kuhn, Alysha Wold, Michael Stolten, Amanda Bennett
  • Patent number: 10703823
    Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: July 7, 2020
    Inventors: David Spiegel, Ryan Murelli, Andrew Zhang
  • Patent number: 10660906
    Abstract: A method for manufacturing a hyaluronan conjugate comprises providing hyaluronan in solution or gel form, reacting the hyaluronan in solution or gel form with anhydride reagent to provide a hyaluronan hemi-ester with a chain of length L between the hyaluronan and the ester group, and subsequently binding the hyaluronan hemi-ester to a pharmaceutically active compound. A hyaluronan conjugate comprises hyaluronan having free hemi-ester-groups and a pharmaceutically active compound bound to the hyaluronan via hemi-ester groups, wherein the hemi-ester groups have a chain length of 2-9 atoms. The hyaluronan conjugate is suitable for use in various methods of treatment in human or veterinary medicine and for preparation of a medicament for use in human or veterinary medicine.
    Type: Grant
    Filed: February 21, 2015
    Date of Patent: May 26, 2020
    Assignee: SYNARTRO AB
    Inventors: Bengt Lindqvist, Rune Ringom
  • Patent number: 10660913
    Abstract: The present invention relates to synergistic compositions which include mixtures of fermentable fibers. These compositions include inulin and arabinoxylan for use in reducing, preventing and/or treating inflammation. The arabinoxylan is partially hydrolyzed arabinoxylan and the ratio of inulin to arabinoxylan and/or partially hydrolyzed arabinoxylan is between 65%/35% by weight and 90%/10% by weight.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: May 26, 2020
    Assignee: Cosucra-Groupe Warcoing SA
    Inventors: Yann Dugenet, Heidi Jacobs, Christian Fougnies, Beatrice Morio, Veronique Coxam, Annick Bernalier
  • Patent number: 10653620
    Abstract: A method of preventing or treating an eye condition includes administering a sterile aqueous ophthalmic solution to an eye for the prevention or treatment of dry eye syndrome or dry eye sign and/or dry eye symptom. The sterile aqueous ophthalmic solution includes about 0.05% to about 0.5% (w/w) of N—(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N—(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 ?mol/g polymer to 280 ?mol/g polymer.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: May 19, 2020
    Inventor: Martin Prinz
  • Patent number: 10646586
    Abstract: The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-3-cyclodextrin (HP?CD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HP?CD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bio availability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: May 12, 2020
    Assignee: ALTERGON S.A.
    Inventors: Alberto Bernareggi, Nadia Puppini, Alessandro Nencioni
  • Patent number: 10625242
    Abstract: A solid substrate for the extraction, stabilization, and storage of proteins is provided. The substrate includes: a polysaccharide, such as melezitose under a substantially dry state. The substrate is configured to extract proteins from a sample and stabilize the extracted proteins in a dry format under ambient conditions for a prolonged period of time. Methods for collecting and recovering the proteins stored in the dry solid substrate are also described.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: April 21, 2020
    Assignee: General Electric Company
    Inventors: Ernest William Kovacs, Frank John Mondello, Erik Leeming Kvam, Bing Li
  • Patent number: 10618982
    Abstract: The present invention relates to a process for the preparation of hyaluronic acid butyrate, or a salt thereof, acceptable for pharmaceutical or cosmetic use or as a medical device, comprising reacting hyaluronic acid, salified with sodium or another alkali metal, in aqueous solution with butyryl-imidazolide in the presence of sodium carbonate. The present invention also relates to pharmaceutical formulations, cosmetic formulations or medical devices containing the hyaluronic acid sodium salt (HA) butyric esters produced by said process.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: April 14, 2020
    Assignee: BMG PHARMA S.P.A.
    Inventors: Luca Stucchi, Rita Gianni, Alessandra Sechi
  • Patent number: 10610601
    Abstract: The disclosure provides, inter alia, polymeric antibiotic compounds such as modified chitosans and methods of use thereof.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: April 7, 2020
    Assignee: The Regents of the University of California
    Inventors: Young Jik Kwon, Julius Edson
  • Patent number: 10588921
    Abstract: Provided is a pharmaceutical composition for the treatment of disorders such as Niemann-Pick disease and GM1 gangliosidosis which are caused by the storage of cholesterol, such as lysosomal storage disease. Also provided is a method for screening for said pharmaceutical compositions that uses iPS cell strains that phenocopy phentotypes of these disorders. Provided is a pharmaceutical composition for the treatment and/or prevention of lysosomal storage disease, characterized by containing hydroxypropyl-?-cyclodextrin as an active ingredient. Also provided are an iPS cell strain derived from patients suffering from intractable disorders and prepared using a new temperature-sensitive Sendai virus vector, and a screening method for pharmaceuticals using said iPS cell strain.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: March 17, 2020
    Inventors: Takumi Era, Tetsumi Irie
  • Patent number: 10588962
    Abstract: The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: March 17, 2020
    Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., UNIVERSITÄTSSPITAL BASEL
    Inventors: Peter H. Seeberger, Pierre Stallforth, Gennaro De Libero, Marco Cavallari
  • Patent number: 10583128
    Abstract: Small compounds that modulate the expression of and/or function of sodium channel, voltage-gated, alpha subunit (SCNxA) are presented. Pharmaceutical compositions containing such small molecules and their use in treating diseases and disorders associated with the expression of SCNxA are also presented.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: March 10, 2020
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Jane H. Hsiao
  • Patent number: 10570167
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: February 25, 2020
    Assignee: Calithera Biosciences, Inc.
    Inventors: Roland J. Billedeau, Jim Li, Lijing Chen